TreeFrog Therapeutics Presents Delivery Strategy for Next Generation 3D Cell Therapy Format for Parkinson’s Disease at the 28th Annual ASGCT Meeting in New Orleans
TreeFrog Therapeutics, a French biotech specializing in cell therapy is the first company to present a clinical-ready delivery strategy for 3D microtissues cell therapy. The validated approach was demonstrated for their 3D neural microtissues cell therapy treatment for Parkinson’s disease.
Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease. It is a progressive disease characterized by the loss of dopaminergic neurons with a mix of motor symptoms (bradykinesia, rigidity, resting tremor) and non-motor symptoms (cognitive deficits, mood disorders, fatigue). Current treatments provide symptomatic relief only. There is a huge unmet need with a prevalence that has doubled in the last 25 years to an estimated 10 million sufferers, and it is expected to double again by 20501,2.
Research into cell replacement strategies for Parkinson’s disease has been ongoing for decades and the promise of cell therapy in the disease has resulted in a dynamic clinical trial landscape. Since 2021, when there were 5 trials in Parkinson’s disease, there have been 15 new trials initiated or planned3.
Most cell therapies rely on single-cell suspensions which, while still holding promise, face specific challenges such as elevated cell death due to anoikis. Next generation 3D formats such as the neural microtissues in development by TreeFrog have emerged as a potential solution as the microtissue is in itself a network, providing protection to the cells and facilitating transplantation.
Peter Andersen, Chief R&D Officer, TreeFrog Therapeutics commented “I am excited to present, for the first time, a validated delivery strategy for a 3D microtissue format cell therapy. The development took 4 years, and I am proud of what the cross-functional team has achieved. 3D formats have huge potential, but the team also had to overcome challenges such as faster sedimentation to ensure homogenization and accurate dose delivery. The team also focused on developing a device using existing components which will facilitate education of use for neurosurgeons and their teams.”
To learn more about this delivery strategy, those attending the ASGCT can attend the poster session and exchange with Peter Andersen:
-
Date: May 15, 2025
Time: 5:30 PM - 7:00 PM - Venue: On-site Poster Hall
- Title: Development of a Delivery Strategy for Neural Microtissues in Parkinson's Disease Cell Therapy (#2039)
- Link to Late-Breaking Abstracts ASGCT Abstracts
About TreeFrog Therapeutics
TreeFrog Therapeutics is a French-based regenerative medicine biotech set to unlock access to cell therapies for millions of patients with a lead program in Parkinson’s disease. TreeFrog is unique in its approach to cell therapy development, bringing together biophysicists, cell biologists and bioproduction engineers to address the challenges of the industry - producing and differentiating cells of quality at unprecedented scale, cost-effectively. To succeed in their mission of Cell Therapy for all, TreeFrog operates a business model that includes its own therapeutic programs and partnerships with leading biotech and industry players. Since 2021, the company has raised $82 million to advance a pipeline of stem cell-based therapies in regenerative medicine.
1Statistics | Parkinson's Foundation
2 Su D et al. Projections for prevalence of Parkinson’s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ. 2025;388:e080952
3Overview of Parkinson's Disease Clinical Trial Landscape. Data on file
View source version on businesswire.com: https://www.businesswire.com/news/home/20250512127233/en/
Contacts
For further information contact
Rachel Mooney
Chief Communications Officer
Rachel.mooney@treefrog.fr
Tel: +33 674063461
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ITRS Recognized in 2025 Gartner® Magic Quadrant™ for Observability Platforms for the First Time16.7.2025 14:00:00 CEST | Press Release
ITRS, a pioneer in real-time monitoring and observability for mission-critical industries, today announced its inclusion in the 2025 Gartner® Magic Quadrant™ for Observability Platforms. ITRS’s transformation into a unified observability platform, purpose-built for demanding and regulated IT environments, is the outcome of sustained investment in product innovation. By consolidating Geneos (application performance), Opsview (infrastructure monitoring), and Uptrends (digital experience monitoring) into a single, powerful platform, ITRS Analytics, the company delivers observability at the speed of the markets. “Our ambition is to redefine observability for industries where downtime isn’t an option,” said Ryan Terpstra, CEO at ITRS. “ITRS Analytics empowers organizations to move beyond IT monitoring to holistic observability, ensuring the systems that power the modern digital economy are always on.” Built for Real-Time Resilience ITRS Analytics offers the ability to ingest and enrich tele
Venture Global and Eni Announce 20-Year LNG Sales and Purchase Agreement16.7.2025 13:00:00 CEST | Press Release
Today, Venture Global, Inc. (NYSE: VG) and Eni S.P.A. of Italy announced the execution of a new Sales and Purchase Agreement (SPA) for the purchase of 2 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from CP2 LNG, Venture Global’s third project, for 20 years. This deal marks Eni’s first ever long-term agreement with a U.S. LNG producer. To date, approximately 13.5 MTPA of CP2 Phase One has been sold, raising the total contracted capacity for all of Venture Global’s projects to 43.5 MTPA. To date, Venture Global has supplied Italy with nearly 40 cargoes of U.S. LNG from its Calcasieu Pass and Plaquemines LNG facilities. “We are honored that Eni, a leading innovator and global gas player, has chosen Venture Global as their first American LNG supplier. Italy is an important ally and trading partner to the United States, and we are grateful for the trust of Eni as our newest customer. This deal marks a significant milestone for the company and is further recognition of our
Veranex Unveils MedTech’s First Innovation CRO (iCRO)—Redefining R&D in a Capital‑Tight Market16.7.2025 13:00:00 CEST | Press Release
Veranex, a global provider of product development and contract research services, today introduced the industry’s first Innovation CRO (iCRO)—an integrated development and research platform engineered to move medical devices and in-vitro diagnostics (IVDs) from concept to commercial success faster, with tighter budget control and a built-in path to payer adoption. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716366338/en/ Veranex launches Innovation CRO for device and diagnostics. iCRO: Innovation Without Waste The Veranex iCRO model is built on four core pillars: Speed & Capital Efficiency – Integrated teams and workflows can cut 3–6 months per development phase and reduce budget variance 18 percent versus transactional (traditional) outsourcing. Flexible partnership tiers—Full Stack, Stage Select, and Strategic Augment—let sponsors deploy only the iCRO services they need while retaining velocity. Evidence Integration
Pluto Labs' 'Strategic Efficiency' AI Outperforms Google & Anthropic Models at a Fraction of the Cost16.7.2025 12:47:00 CEST | Press Release
In the global race to create an 'AI Scientist' capable of independent scientific discovery, Korean startup Pluto Labs is making significant waves. While tech giants like Google and Anthropic define competitive strength by sheer computing power, Pluto Labs introduces 'Scinapse AI,' a groundbreaking model that develops a more effective AI Scientist at just one-tenth of the usual computational cost, achieving overwhelming performance against top models in blind evaluations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715211709/en/ GRAPH: Scientific Idea Generation Performance Comparison - Scinapse AI vs. Google Gemini 2.5 Pro vs. Claude Opus 4 (Evaluation conducted by Pluto Labs) Pluto Labs pioneers a 'Strategic Efficiency' architecture, mirroring how human scientists optimize research. Instead of brute-force computing (like Google's 'Co-scientist'), Scinapse AI smartly delegates inefficient tasks, such as sifting through
Aude Gandon Appointed Chief Digital & Marketing Officer, The Estée Lauder Companies16.7.2025 12:45:00 CEST | Press Release
The Estée Lauder Companies Inc. (NYSE: EL) announced today that Aude Gandon has been appointed Chief Digital & Marketing Officer (CDMO), effective August 1, 2025. Ms. Gandon will report directly to Stéphane de La Faverie, President and Chief Executive Officer, and will join the company's Executive Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716106615/en/ Aude Gandon, Chief Digital & Marketing Officer (CDMO), The Estée Lauder Companies In this newly created role, Ms. Gandon will lead the transformation of the company’s digital, marketing and media ecosystem, shaping end-to-end strategies across its powerful brand portfolio, and will oversee global digital commerce. Her appointment reflects the company’s commitment to evolving its consumer-centric approach and strengthening marketing as a commercial growth engine. “Aude is an exceptional and accomplished global marketing leader with extensive experience transformin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom